The issue of renal safety of zoledronic acid from a nephrologist's point of view

被引：23

作者：

Balla, J

机构：

[1] Univ Debrecen, Med & Hlth Sci Ctr, Dept Nephrol, H-4012 Debrecen, Hungary

[2] Univ Debrecen, Med & Hlth Sci Ctr, Hemodialisys Unit, H-4012 Debrecen, Hungary

来源：

ONCOLOGIST | 2005年 / 10卷 / 05期

关键词：

D O I：

10.1634/theoncologist.10-5-306

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：306 / 308

页数：3

共 24 条

[1] Safety and convenience of a 15-minute infusion zoledronic acid [J].

Berenson, J ;

Hirschberg, R .

ONCOLOGIST, 2004, 9 (03) :319-329

[2]

Berenson JR, 2001, CANCER, V91, P144, DOI 10.1002/1097-0142(20010101)91:1<144::AID-CNCR19>3.0.CO

[3]

2-Q

[4] American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma [J].

Berenson, JR ;

Hillner, BE ;

Kyle, RA ;

Anderson, K ;

Lipton, A ;

Yee, GC ;

Biermann, JS .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3719-3736

[5]

Berenson JR, 2001, CLIN CANCER RES, V7, P478

[6] Recommendations for zoledronic acid treatment of patients with bone metastases [J].

Berenson, JR .

ONCOLOGIST, 2005, 10 (01) :52-62

[7]

BOUNAMEAUX HM, 1983, LANCET, V1, P471

[8]

Chang JT, 2003, NEW ENGL J MED, V349, P1676

[9] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].

COCKCROFT, DW ;

GAULT, MH .

NEPHRON, 1976, 16 (01) :31-41

[10] Chronic kidney disease awareness, prevalence, and trends among US adults, 1999 to 2000 [J].

Coresh, J ;

Byrd-Holt, D ;

Astor, BC ;

Briggs, JP ;

Eggers, PW ;

Lacher, DA ;

Hostetter, TH .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (01) :180-188

← 1 2 3 →